$8.25
▲ +0.1% Today
as of Sep 4, 16:45 ET
Last 30 days
Recent Press Releases & News
Agenus to Participate in Upcoming September Investor Conferences
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Overview
52-week range
$2.71
$8.85
90% of range
Avg surprise (last 3)
-14.5%
Avg reaction (last 2)
+2.8%
50% positive
Latest IV / EM
78%
EM ±12.1% · $8 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.01 | — | — | — | — | financials |
| Mon May 11, 2026 | Mar/2026 | $1.02 | $2.10 | -51.4% | +199.0% | -14.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $1.94 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $1.00 | $-0.78 | -28.2% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-1.03 | $-1.61 | +36.0% | — | +20.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-3.08 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-2.52 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-3.04 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-3.29 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-3.93 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-4.31 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $35M | $34M | — | $30M | $26M | $24M | — | $25M |
| Cost of revenue | $0 | $0 | — | $642,000 | $243,000 | $137,000 | — | $146,000 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $11M | $15M | — | $-5M | $-17M | $-13M | — | $-32M |
| Net income | $-567,000 | $39M | — | $64M | $-30M | $-26M | — | $-67M |
| EPS (diluted) | $-0.01 | $1.02 | — | $1.94 | $-1.00 | $-1.03 | — | $-3.08 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $19M | $35M | $3M | $3M | $10M | $18M | $40M | $45M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $79M | $95M | $133M | $134M | $13M | $23M | $46M | $50M |
| Total assets | $173M | $186M | $227M | $234M | $185M | $200M | $226M | $238M |
| Long-term debt | $30M | $30M | $45M | $24M | $23M | $33M | $30M | $0 |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $-199M | $-228M | $-271M | $-274M | $-336M | $-322M | $-326M | $-272M |